Domača stranNSIS-B • CPH
add
Novozymes
Prejšnji trg. dan.
475,90 kr
Dnevni razpon
474,70 kr - 480,40 kr
Letni razpon
375,90 kr - 480,40 kr
Tržna kapitalizacija
192,02 mrd. DKK
Povprečni obseg
557,47 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
CPH
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 915,85 mio. | 61,70 % |
Stroški poslovanja | 271,75 mio. | 52,62 % |
Čisti dohodek | 31,95 mio. | −60,72 % |
Čista dobičkovnost prihodkov | 3,49 | −75,70 % |
Earnings per share | — | — |
EBITDA | 150,94 mio. | −16,50 % |
Efektivna davčna stopnja | 29,00 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 260,80 mio. | 85,35 % |
Skupna sredstva | 15,25 mrd. | 302,43 % |
Skupne obveznosti | 4,25 mrd. | 119,23 % |
Celoten lastniški kapital | 11,00 mrd. | — |
Shares outstanding | 277,90 mio. | — |
Razmerje P/B | 12,02 | — |
Donosnost sredstev | 1,83 % | — |
Donosnost kapitala | 2,15 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 31,95 mio. | −60,72 % |
Denar iz dejavnosti | 264,05 mio. | 74,01 % |
Denar iz naložb | −27,45 mio. | 70,98 % |
Denar iz financiranja | −186,70 mio. | −205,10 % |
Neto sprememba denarnih sredstev | 55,55 mio. | 902,56 % |
Prost denarni tok | −17,57 mio. | 68,87 % |
Vizitka
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange.
On 12 December 2023, it was announced that Nozozymes and Danish bioscience company Chr. Hansen had obtained regulatory approval for a merger, and on the following day, the name of the combined company was revealed as Novonesis. Wikipedia
Generalni direktor
Datum ustanovitve
2000
Spletno mesto
Zaposleni
10.452
